June 2022 - BioMedWire (BMW)

ThursdayJun 30, 2022 1:38 pm

Virtual Biopsies May Revolutionize Procedures Used in Heart Transplants

Heart transplant patients often undergo cardiac biopsies in the weeks and months after the transplant to check for heart problems and rejection. The procedure, which involves taking a small sample of heart tissue for testing, can be quite invasive. However, thanks to a new technique developed by researchers from St. Vincent’s Hospital Sydney and Victor Chang Cardiac Research Institute, heart transplant survivors won’t have to deal with invasive cardiac biopsies anymore. Scientists have developed a new magnetic resonance imaging (MRI) technique that can allow clinicians to check for signs of heart transplant rejection without hospital admissions and with minimal complications.…

WednesdayJun 29, 2022 12:44 pm

AI May Help Improve Brain Cancer Diagnosis

Traditionally, brain tumors are diagnosed by computer topography scans (CT), magnetic resonance imaging (MRI) or a neurologic exam. However, researchers from the Karl Landsteiner University for Health Sciences (KL Krems) have now discovered a more precise and accurate way of diagnosing brain cancer by using artificial intelligence (AI) combined with physiological imaging. The researchers used several multiclass machine learning techniques to study data sourced from MRIs and classified different brain tumors. They then compared the results produced through machine learning with classifications that were made by human specialists. Although the experts were better at specificity and sensitivity, the researchers discovered…

WednesdayJun 29, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Taps Military Advisors to Address Target Market for PRV-002 Concussion Drug

Odyssey Health is a medical company focused on developing medical products for conditions with unmet needs, one of which is concussion Currently, concussions do not have an FDA-approved treatment Soldiers form a significant population of people who frequently experience multiple concussions throughout their career Concussion has only recently received greater attention as different parties seek to understand the condition and possible treatments Odyssey is at the forefront of this pursuit for treatment and has developed the PRV-002 drug candidate that it intends to use on the military as part of a Phase II clinical trial The company announced the formation…

TuesdayJun 28, 2022 1:36 pm

New Report Says Smoking Amplifies Schizophrenia and Depression Risk

New research has found that smoking can increase an individual's risk of developing depression and schizophrenia. According to a report from the University of Bristol, the risk of developing depression goes up by an estimated 53% to 130% while the risk of developing schizophrenia increases by roughly 52% to 127% when you smoke regularly. The research was shared at the Royal College of Psychiatrists International Congress and will be used to inform the United Kingdom government’s new Tobacco Control Plan. Researchers will also provide the Parliament of the UK with data on the number of smokers in the country who…

TuesdayJun 28, 2022 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Authorizes New Channel Partner to Offer AditxtScore(TM) Amid Rising COVID-19 Cases and Possible Fall/Winter Waves

Aditxt, Inc. is a is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The Company’s product AditxtScore(TM) is a proprietary immune mapping technology designed to provide a personalized profile of the immune system; AditxtScore(TM) for COVID-19 is the Aditxt’s first commercial product Aditxt recently announced it had authorized a new channel partner – Premier Medical Laboratory Services (“PMLS”), a leading advanced medical diagnostics lab –to offer AditxtScore(TM) This announcement comes amid reports warning of a fall and winter COVID-19 wave occasioned by waning immunity or a possible “nasty new variant” Already, the…

MondayJun 27, 2022 2:33 pm

Why More Attention Needs to Be Paid to Paternal Mental Health

We know that pregnancy, giving birth and navigating the first few months as a mother can have an immense toll on women’s mental health. In recent times, there has been an increased push to provide resources for new mothers to help address mental health issues such as postpartum depression. Fathers don’t seem to be getting the same kind of support and resources even though they too experience a multitude of emotions and mental health outcomes after their children are born. Unlike the old days when families had strictly defined gender roles and fathers weren’t as actively involved in their children’s…

MondayJun 27, 2022 9:45 am

Odyssey Health, Inc. (ODYY) Targeting Achievement of Important Milestones, as It Progresses Clinical Trials of Novel Concussion Drug

Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantage The company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussion In an interview with RedChip Companies CEO Dave Gentry, Odyssey CEO Michael Redmond outlined the timelines under which the company is operating as it eyes the commercialization of its novel drug candidate Medical company Odyssey Health (OTC: ODYY) is working to provide life-saving medical solutions…

MondayJun 27, 2022 2:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study

Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substance Kernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeutics Technology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO New data confirms Cybin’s (NEO: CYBN) (NYSE American: CYBN) focus on and commitment to progressing psychedelics to therapeutics. The company’s feasibility study using Kernel Flow confirms the device’s ability to successfully measure the neuro-effect of ketamine (https://ibn.fm/blLwT), based on study results presented at the PSYCH Symposium in London. Cybin has announced that…

MondayJun 27, 2022 1:30 am

Silo Pharma Inc. (SILO) Takes Aim at Alzheimer’s Disease

In October 2021, Silo Pharma (OTCQB: SILO) entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for Alzheimer's Disease (“AD”). SRA’s grant Silo access to world-class research facilities to sponsor potential life-changing research while offering Silo licensing opportunities for groundbreaking psychedelic remedies. Columbia University Irving Medical Center (“CUIMC”), an “internationally recognized leader” in research and therapeutic development, partnered with Silo to study psychedelics’ ability to improve, slow, or even reverse functional decline and memory loss associated with Alzheimer's disease. Associate Professor of Clinical Neurobiology, Dr. Christine Ann Denny, helming the research for Silo,…

FridayJun 24, 2022 1:59 pm

New Research Says Immune Cell Proliferation May Be Associated with Multiple Sclerosis Onset

New research has discovered that there may be a link between higher levels of immune cells in the blood and multiple sclerosis . For the research, scientists studied the genetic data of a large group of individuals with European ancestry. They found that a specific immune cell known as natural killer cells was associated with a 24% rise in the risk of developing multiple sclerosis. The researchers, whose findings were reported in “Frontiers in Immunology,” state that understanding the link between natural killer cells and multiple sclerosis could help them develop potential therapies for this illness. Multiple sclerosis develops when…